Tzankov Alexandar, Zimpfer Annette, Pehrs Ann-Christine, Lugli Alessandro, Went Philip, Maurer Robert, Pileri Stefano, Dirnhofer Stephan
Institute of Pathology, University of Basel, Basel, Switzerland.
Mod Pathol. 2003 Nov;16(11):1141-7. doi: 10.1097/01.MP.0000093627.51090.3F.
Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma arise from B-lymphocytes. However, classical markers of the B-cell phenotype, such as CD20, are present only in about 25% of the cases. The aim of the present study was to assess expression of the B-cell-related antigens CD20, CD79a, and CD138 in classical Hodgkin lymphoma using a tissue microarray consisting of 330 classical Hodgkin lymphoma cases. Expression of CD15, CD20, CD30, CD79a, CD138, and latent membrane protein 1 of Epstein-Barr virus was assessed by immunohistochemistry, and the methodology was validated by direct comparison of CD20 expression on the tissue microarray cores with corresponding large sections. The influence of the number of arrayed sample cores on the obtained expression levels of CD20 was analyzed by comparing the results from single, duplicate, and triplicate cores. Two-hundred fifty-three (77%) of the 330 cases were morphologically representative. CD20 was expressed in 84 cases (33%), CD79a in 26 (10%), and CD138 in 2 (1%), respectively. CD20 and CD79a were co-expressed in 16 cases (P <.005), and expression of CD20 correlated inversely with CD15 (P <.01). Comparing the tissue microarray results with those from conventional sections for expression of CD20 yielded a concordance of 94% (63/67). Examining one, two, and three cores from individual cases revealed positivity for CD20 at 24% (61/253), 32% (82/253), and 33% (84/253), respectively. We conclude that B-cell markers are expressed in 38% of classical Hodgkin lymphoma in the following rank order: CD20>CD79a>>CD138. The use of two cores per tissue sample renders the tissue microarray technology effectively representative and thus very useful for high-throughput evaluation of heterogeneously expressed markers in classical Hodgkin lymphoma.
经典型霍奇金淋巴瘤的霍奇金和里德-斯腾伯格细胞起源于B淋巴细胞。然而,B细胞表型的经典标志物,如CD20,仅在约25%的病例中存在。本研究的目的是使用包含330例经典型霍奇金淋巴瘤病例的组织芯片,评估经典型霍奇金淋巴瘤中B细胞相关抗原CD20、CD79a和CD138的表达情况。通过免疫组织化学评估CD15、CD20、CD30、CD79a、CD138以及爱泼斯坦-巴尔病毒潜伏膜蛋白1的表达,并通过将组织芯片核心上CD20的表达与相应的大体切片进行直接比较来验证该方法。通过比较单芯、双芯和三芯的结果,分析了排列样本芯数量对获得的CD20表达水平的影响。330例病例中有253例(77%)在形态学上具有代表性。CD20在84例(33%)中表达,CD79a在26例(10%)中表达,CD138在2例(1%)中表达。CD20和CD79a在16例中共同表达(P<.005),CD20的表达与CD15呈负相关(P<.01)。将组织芯片结果与传统切片中CD20的表达结果进行比较,一致性为94%(63/67)。检查单个病例的一芯、两芯和三芯,CD20阳性率分别为24%(61/253)、32%(82/253)和33%(84/253)。我们得出结论,38%的经典型霍奇金淋巴瘤表达B细胞标志物,其顺序如下:CD20>CD79a>>CD138。每个组织样本使用两芯使组织芯片技术具有有效的代表性,因此对于经典型霍奇金淋巴瘤中异质性表达标志物的高通量评估非常有用。